Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Stock Exchange Release April 25, 2016 at 5:15 pm local time (EEST)
The Annual General Meeting (AGM) of Biohit Oyj held on Monday April 25, 2016 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2015.
Distribution of dividends
The AGM approved the Board of Directors proposal that no dividend shall be paid for the financial period ended on December 31, 2015.
Members of the Board of Directors
The AGM decided that the number of members of the Board of Directors would be six (6) and elected the following Board members until the end of the next AGM: current members Professor Osmo Suovaniemi, Professor Mikko Salaspuro, Commercial Counselor Eero Lehti, M. Sc. Eng. Seppo Luode, Managing Director Franco Aiolfi and Master of Political Science Janina Andersson.
Additionally, the AGM decided that the Chairman of the Board of Directors would be paid a meeting fee of EUR 1,600 and the other Board members would be paid a meeting fee of EUR 1,500.
Election and remuneration of the Auditor
The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company’s auditor until the end of the next AGM. The auditor will be paid remuneration against the auditor’s invoice.
Authorization of the Board of Directors to decide on the issue of shares and to issue special rights entitling the receipt of shares
The AGM decided to authorise the Board to decide on the issue of shares and to issue special rights referred to in Chapter 10, section 1 of the Limited Liability Companies Act entitling the receipt of shares with the following terms and conditions:
The maximum number of new Series B shares to be issued pursuant to the special rights is 3,000,000, which corresponds to approximately 26.4% of the company’s all existing Series B shares.
The authorisation includes the Board of Directors’ entitlement to decide on all terms and conditions regarding the issue of special rights. The issue of shares and the issue of special rights entitling to the receipt of shares can occur deviant from the subscription right of the shareholders (special issue). The authorization remains valid for two years from the resolution of the GM and the authorisation replaces the former authorisations.
All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by May 2, 2016 on the company’s website (www.biohithealthcare.com /investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com